Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNP-2092 in Prosthetic Joint Infection
NCT07858916Phase 2Recruiting
- Sponsor
- TenNor Therapeutics
- Start
- Oct 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifaquizinone in prosthetic joint infection (PJI) (3 arms), sponsored by TenNor Therapeutics. Primary endpoint: Treatment failure rate at 6 months. Started Oct 2026; status: recruiting.
02
Drugs
rifaquizinone
03
Conditions
prosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT07858916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07858916.